Voyager: Crossing The Blood-Brain Barrier, Competitors, And Investment Relevance
Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's ...
precisionmedicineonline1d
At Some Hospitals, Expert Panels Help Guide Anti-Amyloid Drug Decisions for Alzheimer's Patients
These boards are cropping up around the US as neurologists acclimate to a new class of drugs, but not everyone agrees such ...
devdiscourse2d
From Drug Approvals to Global Health Funding: Key Updates in Health Sector
This article highlights recent developments in healthcare, including the U.S. FDA's approval of Alzheimer's and diabetes ...
verywellhealth2d
New Maintenance Dosing Option for Alzheimer's Drug Leqembi Offers Flexibility
The Food and Drug Administration (FDA) has approved a new maintenance dosing schedule for Leqembi, a monoclonal antibody ...
Breaking Down Biogen: 18 Analysts Share Their Views
The 12-month price targets, analyzed by analysts, offer insights with an average target of $214.78, a high estimate of ...
devdiscourse2d
Global Health Headlines: Profit Surges, Flu Cases, and Policy Shifts
Recent health news includes a profit boost for Swedish manufacturer Getinge, a human case of bird flu detected in the UK, and ...
PharmaTimes2d
FDA approves new Alzheimer’s treatment regimen
The US Food and Drug Administration (FDA) has approved Eisai and Biogen’s Supplemental Biologics License Application for once ...
Explainer-Trump Tariffs on Chips and Drugs Would Hit U.S. Allies in Asia
Imposing tariffs on imported pharmaceuticals could weigh on Japan, home of major drugmakers such as Takeda, Astellas, Daiichi ...
Managed Healthcare Executive2d
FDA Approves New IV Maintenance Dose of Leqembi
A monthly 10 mg/mL maintenance dose of Leqembi had the same effects on mild Alzheimer’s symptoms as biweekly dose, research ...
cweb3d
Biogen Shares Rise on FDA Approval for Alzheimer’s Drug, But CWEB Analyst Insight Highlights Market Impact
Biogen Inc. (BIIB) saw its stock climb 1.7% on Monday afternoon, reaching a nearly two-week high following positive ...
MM&M3d
Biogen, Eisai receive FDA nod for monthly Leqembi IV maintenance dosing
The Japanese and American based pharma companies announced a win for their Alzheimer’s treatment, which has faced some negative backlash over the last year.